GW’s cannabinoid-based Epidiolex scores another Phase III epilepsy victory
The drug showed positive results in a 210-patient study in patients experiencing treatment-resistant seizures from tuberous sclerosis complex, a rare form of epilepsy.
NeuroSigma wins FDA nod for first non-drug ADHD treatment
The company's cell phone-sized device delivers low-level electric stimulation to the trigeminal nerve through a patch placed on a patient's forehead.
The Role of Consultants in Tackling Healthcare Expenses
To ensure effective cost mitigation, employers can’t wait for the market to adjust — they have to punch first.
Bain invests $350M in new company Cerevel to develop Pfizer’s neuroscience pipeline
Cerevel will take on several clinical and preclinical candidates from Pfizer, which divested from neuroscience this year and will take a 25 percent stake in the new company.
System1 Biosciences raises $25M in Series A round for neurotherapeutics discovery platform
System1 Biosciences' platform combines stem cell lines from patients with brain diseases with a three-dimensional in vitro system and data analytics.
GW Pharmaceuticals gets first FDA approval for CBD-based drug
The FDA approved the cannabis-based drug for treating seizures in two severe forms of epilepsy.
Start-up plans to target epilepsy using gut microbiota
Bloom Science plans to have its proprietary gut bacteria in the clinic for hard-to-treat patients in the next 12-18 months.
presented by
The Top 5 Home Care Franchise Opportunities in the U.S.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
A wearable using AI to identify severe seizures and warn caregivers gains FDA approval
By passively collecting seizure data, Empatica's device could help patients share medical information with clinicians and make that data easier to manage.
Blackfynn gets $2.3M, adds partners for data integration tools to accelerate neuroscience research
Medical researchers frequently spend the majority of their time formatting research data and 10 percent of their time actually using it. Blackfynn hopes its platform will aid translational research and therapeutic product development.
This entrepreneur’s device is designed to protect the tongue during a seizure
NeuroVice's device is designed to provide a safe way to protect tongues and minimize salivation during seizures.
Smart watches are opening up seizure tracking (Updated)
The goal is to track the severity and length of the seizure using sensors such as an accelerometer and a gyroscope as well as a memory test when the user comes out of the event.
Solving Healthcare’s Provider Data Problem Starts with Interoperability
Break down the silos. Take control of your provider data.
Aprecia Pharmaceuticals brings in $35M to move forward with 3D printed dissolving drug pipeline
Aprecia Pharmaceuticals is getting closer to commercializing SPRITAM, its 3D printed formulation of levetiracetam, which is a well-established medication used by patients with epilepsy.
Convenient timing, Shkreli: Turing’s epilepsy drug gets fast-tracked by FDA
The day after news broke that Turing Pharmaceuticals' Daraprim has a new competitor on the market, CEO Martin Shkreli announced the company's gotten fast-track status for its experimental epilepsy drug.
Turing announces first IND application for new brain disorder drug (post-Daraprim pricing controversy)
Turing isn't just buying drugs and bumping up prices. It is actually putting a focus on new drugs, which is exemplified with its recent investigational new drug application.
Epilepsy device developer NeuroSigma has withdrawn its $50M IPO plans
The Los Angeles-based company developing its drug-resistant epilepsy system has officially backed out of its IPO plans.
Wearables help manage neurological disorders, predict symptoms
New, wearable technology not only helps monitor symptoms automatically, it may be able to predict seizures and disease progression in patients with neurological disorders.